Honing, Maarten https://orcid.org/0000-0002-9747-6966
Reijnders-Boerboom, Gabby
Dell-Kuster, Salome
van Velzen, Monique
Martini, Chris
Valenza, Franco
Proto, Paolo
Cambronero, Oscar Díaz
Broens, Suzanne
Panhuizen, Ivo
Roozekrans, Margot
Fuchs-Buder, Thomas
Boon, Martijn
Dahan, Albert
Warlé, Michiel
Funding for this research was provided by:
Merck Sharp and Dohme (58426)
Article History
Received: 21 April 2021
Accepted: 15 September 2021
First Online: 26 October 2021
Declarations
:
: The local MREC (Leiden-Den Haag-Delft) has granted approval for the trial and all amendments (committee identifier P19.065) in the Netherlands. Local approval will be obtained in all participating centers in France, Italy, and Spain. This trial protocol was designed in accordance with the most recent version of the Declaration of Helsinki (2013). The trial follows local Good Clinical Practice guidelines and Good Research practice [19]. Patients can only participate after providing consent, as described in paragraph {26a}.
: Not applicable.
: MB, CM, AD, and MW received speaker fees from MSD. The other authors declare no competing interests.